Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Sulfasalazine for the treatment of ankylosing spondylitis: relic or niche medication?

Ward MM.

Arthritis Rheum. 2011 Jun;63(6):1472-4. doi: 10.1002/art.30225. No abstract available.

2.

New-onset psoriasis associated with etanercept therapy.

Chen LA, Su LH, Chang YJ, Hsu YL, Tsai TH.

J Dermatol. 2010 Apr;37(4):378-80. doi: 10.1111/j.1346-8138.2010.00789.x. Review. No abstract available.

PMID:
20507411
3.

New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy.

Sieper J, Braun J.

Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii58-61. Review.

4.

[New and old therapeutic options in ankylosing spondylitis--is there an indication for sulfasalazine?].

Braun J, Sieper J.

Z Rheumatol. 2002 Apr;61(2):151-8. Review. German. No abstract available.

PMID:
12056292
5.

TNF antagonists for ankylosing spondylitis.

[No authors listed]

Drug Ther Bull. 2005 Mar;43(3):19-22. Review.

PMID:
15762384
6.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

7.

Sulfasalazine for ankylosing spondylitis.

Chen J, Liu C.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD004800. Review. Update in: Cochrane Database Syst Rev. 2014;11:CD004800.

PMID:
15846731
8.

Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.

Sieper J, Appel H, Braun J, Rudwaleit M.

Arthritis Rheum. 2008 Mar;58(3):649-56. doi: 10.1002/art.23260. Review. No abstract available.

9.

Biologic therapies in the spondyloarthritis: new opportunities, new challenges.

Braun J, Brandt J, Listing J, Rudwaleit M, Sieper J.

Curr Opin Rheumatol. 2003 Jul;15(4):394-407. Review.

PMID:
12819466
10.

[The role of biologic agents in the therapy of ankylosing spondylitis].

Géher P, Nagy MB, Péntek M, Tóth E, Brodszky V, Gulácsi L.

Orv Hetil. 2006 Jul 2;147(26):1203-13. Review. Hungarian.

PMID:
16898082
11.

Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.

Henderson C, Davis JC.

Nat Clin Pract Rheumatol. 2006 Apr;2(4):211-8. Review.

PMID:
16932687
12.

Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade.

Paul S, Keat A.

Rheumatology (Oxford). 2005 Jan;44(1):17-23. Epub 2004 Aug 24. Review. No abstract available.

PMID:
15328421
13.

[Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis].

Brandt J, Sieper J, Braun J.

Z Rheumatol. 2004 Jun;63(3):203-10. Review. German.

PMID:
15224223
14.

[Biological treatment of ankylosing spondylitis].

Freiesleben S, Schou M.

Ugeskr Laeger. 2008 Jun 9;170(24):2140-5. Review. Danish.

PMID:
18565298
15.
16.

Development of sarcoidosis during etanercept therapy.

González-López MA, Blanco R, González-Vela MC, Fernández-Llaca H, Rodríguez-Valverde V.

Arthritis Rheum. 2006 Oct 15;55(5):817-20. Review. No abstract available.

17.
18.

Disease-modifying anti-rheumatic drugs in rheumatoid arthritis and ankylosing spondylitis.

Haibel H, Specker C.

Clin Exp Rheumatol. 2009 Jul-Aug;27(4 Suppl 55):S159-63. Review.

PMID:
19822065
19.

Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs.

van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA.

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S67-70. Review.

PMID:
12463451
20.

Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H.

Ann Rheum Dis. 2002 Dec;61 Suppl 3:iii51-60. Review.

Supplemental Content

Support Center